Please upgrade your browser.
The Department of Defense Peer Reviewed Cancer Research Program (PRCRP) has $50 Million dollars to invest for FY2016. One of the cancers they would like to have better represented among the proposals received is kidney cancer. There are multiple award mechanisms including a translational science team award for $1 million dollars.
Seven new medicines have been approved since 2005 for advanced kidney cancer...
The average age at diagnosis is 64 in whites, in whom kidney cancer is rare under age 45. However, in Nigeria, kidney cancer tends to occur earlier, with the average age of occurrence being in the forties.
Tweaking cholesterol levels with a simple pill may boost the effectiveness of new immunotherapy drugs that are starting to revolutionize the treatment of cancers, experiments in mice suggest.
A comprehensive molecular analysis of 894 primary renal cell carcinomas resulted in nine subtypes defined by systematic analysis of five genomic data platforms. Each major histologic types represent substantial molecular diversity.
The research project consists of a one-time telephone interview lasting 60 minutes. In appreciation of your time and valuable contribution, you will receive an honorarium of $200 payable upon successful completion of the telephone interview.
Adding core-needle biopsy to other clinical care may help improve outcomes for some patients with renal cell carcinoma...
Programmed death ligand 1 (PD-L1) expressed on the tumour cell surface, or on neighbouring host immune cells in the tumour microenvironment, engages the programmed death 1 (PD-1) receptor on activated cytotoxic T cells and thus downregulates the tumour-directed host immune response.
Natural killer cells usually protect the body from harm, but a team from the Southern Illinois University School of Medicine, USA, has been investigating the unexpected role these cells play in the pathology of kidney cancer...
Rutgers Cancer Institute of New Jersey Collaborates with Big Ten Cancer Research Consortium on Clinical Trial for Metastatic Kidney Cancer
n conjunction with the Big Ten Cancer Research Consortium (BTCRC), Rutgers Cancer Institute of New Jersey has opened a clinical trial for patients with kidney cancer that has spread to other parts of the body (metastatic).
|Powered by NeonCRM|